BI 409306
BI 409306 is a pharmaceutical drug with 18 clinical trials. Historical success rate of 88.9%.
Success Metrics
Based on 16 completed trials
Phase Distribution
Phase Distribution
14
Early Stage
4
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
88.9%
16 of 18 finished
11.1%
2 ended early
0
trials recruiting
18
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year
This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months
BI 409306 Cardiac Safety Trial in Healthy Volunteers
This Study in Healthy Men and Women Tests How the Body Takes up BI 409306
Investigation of Pharmacokinetic Drug-drug Interaction of BI 409306 and Donepezil in Healthy Male and Female Subjects
Clinical Trials (18)
This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year
This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months
BI 409306 Cardiac Safety Trial in Healthy Volunteers
This Study in Healthy Men and Women Tests How the Body Takes up BI 409306
Investigation of Pharmacokinetic Drug-drug Interaction of BI 409306 and Donepezil in Healthy Male and Female Subjects
Pharmacokinetics of BI 409306 After a High Fat, High Caloric Meal and After a Single Oral Dose Given at Bed Time in Healthy Volunteers
Safety and Tolerability of BI 409306 in Patients With Schizophrenia
Safety Tolerability and Pharmacokinetic of BI 409306
Drug Drug Interaction Trial With Strong CYP3A4 Inhibitor (Itraconazole) in CYP2C19 Extensive Metabolizers and Poor Metabolizers
Assessment of Exposure of BI 409306 in Cerebrospinal Fluid (CSF) Relative to Plasma as Well as to Evaluation of the Effect of Different Doses of BI 409306 on the cGMP (Cyclic Guanosine Monophosphate) Levels in CSF in Healthy Male Volunteers
This Study Tests in Healthy Korean Women Which Effects BI 409306 and a Birth-control Pill Have on Each Other
This Study in Healthy Men and Women Tests Whether BI 409306 Has an Effect on the ECG (Thorough QT Study)
A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 409306
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses
Drug-drug Interaction Trial Between Rifampicin and BI 409306 in Healthy Volunteers
Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo
BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.
All 18 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 18